

Ref. No: 1524
Date: 05/02/25
Subject: biologic medicines in gastroenterology

REQUEST

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Vedolizumab

Q2. Could you please provide the numbers of patients treated for Crohn's Disease in the last 3 months with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilars
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Risankizumab
- Upadacitinib
- Ustekinumab - Sterala
- Ustekinumab Biosimilar

- Vedolizumab

RESPONSE

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira - <5
- Adalimumab Biosimilar - 197
- Etrasimod – 0
- Filgotinib - 15
- Golimumab - <5
- Infliximab – Remicade - <5
- Infliximab Biosimilar - 151
- Mirikizumab - <5
- Ozanimod - <5
- Risankizumab - 25
- Tofacitinib - 16
- Upadacitinib - 15
- Ustekinumab – Stelara - 79
- Ustekinumab Biosimilar - 94
- Vedolizumab - 118

Q2. Could you please provide the numbers of patients treated for Crohn's Disease in the last 3 months with the following biologic drugs:

- Adalimumab – Humira - 0
- Adalimumab Biosimilars - 25
- Golimumab - 0
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 34
- Risankizumab - <5
- Upadacitinib - 0
- Ustekinumab – Sterala - <5
- Ustekinumab Biosimilar - 21
- Vedolizumab - 12

Due to the low number of patients receiving the some of the above medications which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.